BACKGROUND: Despite the rise in publicly available cancer information, little is known about the association between patient information seeking and the adoption of cancer technologies. The authors of this report investigated the relation between patient information seeking and awareness about and receipt of novel targeted therapy (TT) for colon cancer among patients for whom therapy is approved by the US Food and Drug Administration (FDA) and among patients for whom therapy is not FDA approved. METHODS: A retrospective, population-based survey of 633 colon cancer patients were identified through the Pennsylvania Cancer Registry. Outcome measures were self-reported awareness about and receipt of TT (bevacizumab and cetuximab). RESULTS: After adjusting for sociodemographic characteristics, high levels of treatment information seeking were associated strongly with hearing about TT (odds ratio [OR], 2.83; 95% confidence interval [CI], 1.49-5.38) and receiving TT (OR, 3.22; 95% CI, 1.36-7.62). These associations were present for patients with metastatic disease, for whom the use of TT is FDA approved, and for patients with localized disease, for whom the use of TT is not FDA approved (P for interactions = .29). Internet use (OR, 2.88; 95% CI, 1.40-5.94) and newspaper/magazine use (OR, 3.44; 95% CI, 1.34-8.84) were associated with hearing about TT. Seeking information from nontreating physicians was associated with hearing about TT (OR, 1.95; 95% CI, 1.03-3.68) and receiving TT (OR, 2.64; 95% CI, 1.16-5.97). CONCLUSIONS: Patient information seeking was related to the adoption of TT for colon cancer in both appropriate and inappropriate clinical settings. These findings emphasize the importance of exploring patient influence on physician prescribing patterns and understanding the impact of information seeking on cancer outcomes. (c) 2009 American Cancer Society
BACKGROUND: Despite the rise in publicly available cancer information, little is known about the association between patient information seeking and the adoption of cancer technologies. The authors of this report investigated the relation between patient information seeking and awareness about and receipt of novel targeted therapy (TT) for colon cancer among patients for whom therapy is approved by the US Food and Drug Administration (FDA) and among patients for whom therapy is not FDA approved. METHODS: A retrospective, population-based survey of 633 colon cancerpatients were identified through the Pennsylvania Cancer Registry. Outcome measures were self-reported awareness about and receipt of TT (bevacizumab and cetuximab). RESULTS: After adjusting for sociodemographic characteristics, high levels of treatment information seeking were associated strongly with hearing about TT (odds ratio [OR], 2.83; 95% confidence interval [CI], 1.49-5.38) and receiving TT (OR, 3.22; 95% CI, 1.36-7.62). These associations were present for patients with metastatic disease, for whom the use of TT is FDA approved, and for patients with localized disease, for whom the use of TT is not FDA approved (P for interactions = .29). Internet use (OR, 2.88; 95% CI, 1.40-5.94) and newspaper/magazine use (OR, 3.44; 95% CI, 1.34-8.84) were associated with hearing about TT. Seeking information from nontreating physicians was associated with hearing about TT (OR, 1.95; 95% CI, 1.03-3.68) and receiving TT (OR, 2.64; 95% CI, 1.16-5.97). CONCLUSIONS:Patient information seeking was related to the adoption of TT for colon cancer in both appropriate and inappropriate clinical settings. These findings emphasize the importance of exploring patient influence on physician prescribing patterns and understanding the impact of information seeking on cancer outcomes. (c) 2009 American Cancer Society
Authors: M Brodie; R E Flournoy; D E Altman; R J Blendon; J M Benson; M D Rosenbaum Journal: Health Aff (Millwood) Date: 2000 Nov-Dec Impact factor: 6.301
Authors: Rebecca D Pentz; Anne L Flamm; Jeremy Sugarman; Marlene Z Cohen; G Daniel Ayers; Roy S Herbst; James L Abbruzzese Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: Barbara Mintzes; Morris L Barer; Richard L Kravitz; Ken Bassett; Joel Lexchin; Arminée Kazanjian; Robert G Evans; Richard Pan; Stephen A Marion Journal: CMAJ Date: 2003-09-02 Impact factor: 8.262
Authors: Nehama Lewis; Lourdes S Martinez; Derek R Freres; J Sanford Schwartz; Katrina Armstrong; Stacy W Gray; Taressa Fraze; Rebekah H Nagler; Angel Bourgoin; Robert C Hornik Journal: Health Commun Date: 2011-09-20
Authors: David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock Journal: J Cancer Res Clin Oncol Date: 2013-03-02 Impact factor: 4.553
Authors: Andy S L Tan; Mihaela Moldovan-Johnson; Stacy W Gray; Robert C Hornik; Katrina Armstrong Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-11-01 Impact factor: 4.254
Authors: Mark Lawler; Deborah Alsina; Richard A Adams; Annie S Anderson; Gina Brown; Nicola S Fearnhead; Stephen W Fenwick; Stephen P Halloran; Daniel Hochhauser; Mark A Hull; Viktor H Koelzer; Angus G K McNair; Kevin J Monahan; Inke Näthke; Christine Norton; Marco R Novelli; Robert J C Steele; Anne L Thomas; Lisa M Wilde; Richard H Wilson; Ian Tomlinson Journal: Gut Date: 2018-01 Impact factor: 23.059